Tamtam Try Tamtam free
USANA Health Sciences logo

USANA Health Sciences account plan

Science-driven nutritional supplement company

At a glance

USANA Health Sciences makes science-based nutritional supplements sold by direct selling and Hiya, with $925.3 million FY2025 net sales.

USANA Health Sciences (NYSE: USNA, Salt Lake City, Utah) develops and manufactures science-based nutritional supplements, functional foods and personal care products. It historically sold only through independent Brand Partners and Preferred Customers, and now runs an omni-channel platform after acquiring Rise and a 78.85% stake in Hiya Health Products: direct selling, direct-to-consumer, Amazon and retail. FY2025 net sales were $925.3 million (+8.3%), but net earnings attributable to USANA fell 74.4% to $10.8 million; China was approximately 41.3% of net sales. It had approximately 1,570 employees (FTE) in 22 countries.

Business units

Strategic priorities

Omnichannel transformation
Management aims to evolve USANA from a single channel direct selling company into a diversified omnichannel health and wellness company, which it also frames as reducing dependence on China.
Grow active customers
Growing the active customer base is the top priority, through brand investment, Brand Partner plan adjustments phased in through 2027, and women's and kids' product launches in 2027.
Technology modernisation and AI
USANA plans to modernise core systems by adopting best-in-practice third-party platforms and to use AI, rather than building everything in-house.
Scale Hiya and Rise
Hiya's sales outlook was raised to $130 million with club retail entry planned early Q1 2027; Rise will be in about 4,100 Target and grocery stores by year end.
Operational efficiency
The Q4 2025 cost realignment affected about 10% of the workforce for roughly $10 million of net savings, and more manufacturing is being brought in-house.

Latest results

In Q3 2026 (quarter ended October 3, 2026), net sales fell 3.6% to $205.9 million (5.6% excluding currency) and the net loss attributable to USANA was $5.6 million, or $(0.30) per diluted share. Core Nutritional sales fell 3.1% while Hiya grew 2.3% and Rise fell 44.8%. Nine-month net sales were $679.4 million, with a diluted loss per share of $(1.05) mainly due to the Hiya goodwill impairment. The FY2026 outlook is net sales approaching $900 million and adjusted EBITDA of approximately $77 million, down from $80.5 million.

Investments and deals

In-house manufacturing
Hiya products and powdered drink mixes are moving into USANA's own facilities, with more personal care and skincare made in-house.
Inventory for retail expansion
Inventory rose $35 million to $107 million at the end of 2025, about 80% of it for Rise (Protein Pop at Costco) and Hiya (Target, Canada, UK).
Castle Hill sale
The sale of the Castle Hill, New South Wales office and warehouse settled October 12, 2026, with an estimated pre-tax gain of $8,230 thousand in Q4 2026.
Acquisitions
USANA expects to keep pursuing health and wellness acquisitions for vertical integration, category, channel and geographic expansion.

Challenges and risks

Shrinking core customer base
Core nutritional active Customers fell 14.8% in FY2025 and 8.2% in Q3 2026, with every region outside Southeast Asia Pacific declining in constant currency.
China dependence and regulation
Greater China is the largest market, BabyCare's model has not been approved by the Chinese government, and US-China tensions and tariffs are named risks.
High tax rate
The effective tax rate was 72.4% in FY2025 because revenue and costs sit in different geographies; guidance for 2026 was 55%-60%.
Venture profitability
Hiya's SG&A rose to 86.2% of segment sales on advertising, and Rise had a negative gross margin in Q3 2026; management is not satisfied with Rise's results.

What leadership says

“we must move with greater speed, focus, relevancy, and precision”

Kevin Guest, Chairman and Chief Executive Officer · Q4 and fiscal 2025 earnings call, February 18, 2026

“Growing our active customer base remains our top priority.”

Kevin Guest, Chairman and Chief Executive Officer · Q3 2026 earnings call, November 4, 2026

“we're not satisfied with Rise Wellness' results”

Kevin Guest, Chairman and Chief Executive Officer · Q3 2026 earnings call, November 4, 2026

Where a supplier can help

Third-party IT platforms and AI
Core-system modernisation explicitly favours outside platforms and AI, opening doors for commerce, CRM, ERP and AI vendors.
Customer acquisition and retention
Growing active customers and Hiya subscriber retention are top priorities; loyalty, marketing analytics and digital acquisition tools fit.
Retail and club distribution
Hiya and Rise expansion into Target, Costco and club stores, with lumpy orders, calls for retail execution and demand-planning support.
Manufacturing and supply chain
Bringing Hiya and other products in-house and managing elevated inventory create needs for equipment, packaging and inventory tools.

Tamtam's reading of the priorities and challenges above, not the company's own words.

Selling to companies like USANA Health Sciences?

Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.

Find similar companies

Key documents

Read in full by Tamtam; each summary links to the document itself.

Questions about USANA Health Sciences

What does USANA Health Sciences do?

It develops and manufactures science-based nutritional supplements, functional foods and personal care products, sold through direct selling (Brand Partners), Hiya's direct-to-consumer subscriptions, Amazon and retail.

What is USANA's revenue?

FY2025 net sales were $925.3 million. The FY2026 outlook is net sales approaching $900 million.

How many employees does USANA have?

Approximately 1,570 employees (FTE) in 22 countries, 41% in the United States and 28% in China.

Who leads USANA?

Kevin Guest reassumed the CEO role in January 2026 and remains Chairman; G. Douglas Hekking is CFO and Walter Noot is COO.

Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)